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EpitopesThe dengue virus (DENV) nonstructural protein 1 (NS1) is an immunogenic protein that holds potential for
the development of vaccines and diagnostic reagents; however, the epitopes of NS1 have not been
comprehensively mapped. We mapped B-cell linear epitopes on NS1 using 149 monoclonal antibodies with
DENV serotype speciﬁcity and cross-reactivity as well as antisera from 27 mice immunized with the four
DENV serotypes. Epitope recognition analysis was performed using a set of 15-mer sequential overlapping
peptides that spanned the entire NS1 protein from DENV-1. This strategy identiﬁed three regions of NS1 that
are DENV-1 serotype-speciﬁc epitopes, namely amino acid residues 1–15, 71–85, and 338–352. We also
identiﬁed ﬁve group-speciﬁc B-cell epitopes that were highly conserved among isolates of the four DENV
serotypes. These novel immunodominant serotype- and group-speciﬁc B-cell epitopes of DENV NS1 may aid
the development of new dengue vaccines and diagnostic assays.
© 2009 Elsevier Inc. All rights reserved.Introduction
Dengue, caused by dengue virus (DENV), is a major public health
problem in over 100 tropical and subtropical countries (Mackenzie et
al., 2004). DENV belongs to the Flaviviridae family, which also includes
yellow fever virus (YFV), West Nile virus (WNV), Japanese enceph-
alitis virus (JEV), and tick-borne encephalitis virus (TBEV). DENV is
classiﬁed into four serotypes, DENV-1, -2, -3, and -4. An infection with
any of these serotypes can cause clinical manifestations including
dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue
shock syndrome (DSS) (George and Lum, 1997). Subsequent
heterologous infections may increase the risk of the developing DHF
or DSS (Kurane and Ennis, 1992). Since protection against heterolo-
gous serotype infections is both partial and transient, people who live
in epidemic areas may be susceptible to four DENV infections in their
lifetime (Kanakaratne et al., 2009). Thus, the cocirculation of virus
serotypes in a community is the most common risk factor associated
with the emergence of DHF or DSS, the most severe forms of dengue
(Gubler, 1998). Since no vaccine is available that elicits long-term
protective immunity against all four DENV serotypes (Edelman, 2007;
Whitehead et al., 2007), the development of a DENV vaccine remains a
global public health challenge. A better understanding of how viral
components correlate with immune protection and pathogenic
determinants is likely to contribute to the development of an effective
vaccine. In addition, given the lack of an effective vaccine for
controlling dengue, early identiﬁcation of multiple DENV infectionsll rights reserved.in the acute phase of the illness is important for reducing morbidity
and mortality associated with DHF and DSS, as well as for
epidemiological control in areas where multiple ﬂaviviruses are
endemic (De Paula and Fonseca, 2004).
The DENV nonstructural protein 1 (NS1) has been identiﬁed as a
candidate antigen for vaccine development (Costa et al., 2006, 2007).
Immunization with NS1 or passive administration of anti-NS1 MAbs
can protect mice against a lethal virus challenge (Chung et al., 2006;
Falgout et al., 1990; Henchal et al., 1988; Schlesinger et al., 1987).
However, NS1 is also associated with dengue pathogenesis, which
may elicit autoantibodies that react with platelet and extracellular
matrix proteins to induce platelet dysfunction and bleeding (Chang
et al., 2002, 2009; Falconar, 1997; Sun et al., 2007), directly enhance
infection (Alcon-LePoder et al., 2005), and promote the formation of
terminal complement complex by binding the human complement
regulatory protein clusterin (Kurosu et al., 2007). Dengue patho-
genesis can also result in endothelial cell apoptosis and immune
activation via anti-NS1 antibody-dependent complement-mediated
cytolysis (Lin et al., 2005, 2003, 2002, 2008) or by binding of soluble
NS1 and subsequent recognition by anti-NS1 antibodies (Avirutnan
et al., 2007). NS1has also been identiﬁed as being both a group-speciﬁc
and serotype-speciﬁc determinant and as an early serotyping
diagnostic marker (Falconar and Young, 1991; Henchal et al., 1987;
Shu et al., 2000; Chen et al., 2002). Serotyping assays have been
developed using serotype- or group-speciﬁc monoclonal antibodies
(MAbs) to differentiate the four serotypes of DENV infections (Qiu et
al., 2009; Xu et al., 2006; Young et al., 2000). Identiﬁcation and
characterization of antigenic NS1 epitopes may help us elucidate the
dengue pathogenesis, accelerate vaccine design, and further develop
immunodiagnostic reagents. In our previous study, we generated and
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group-speciﬁc epitopes on DENVNS1 (Qiu et al., 2009; Xu et al., 2006).
In the present study, we identiﬁed several immunodominant epitopes
on NS1 using a panel of MAbs and antisera raised in mice against the
four DENV serotypes. Characterization of the immunodominant sites
provides information that has great potential value for developing
dengue diagnostic reagents and for designing better dengue vaccines.
Results
Serotype speciﬁcity and cross-reactivity of MAbs raised against NS1
A total of 149 hybridoma cell lines that stably producedMAbswere
established on the basis of their strong reactivity with both
recombinant NS1 protein and DENV-infected cell lysates as antigen
in the ELISA. Immunoﬂuorescence assays (IFA) showed that all MAbs
recognized the native NS1 antigen in DENV-infected cells. Most of the
MAbs were IgG1 subtype antibodies. The serotype speciﬁcity and
cross-reactivity of the MAbs were further characterized by testing
their reactivity with each virus serotype by ELISA and Western blot
analysis. Of 149 MAbs, 25 MAbs, 20 MAbs (Qiu et al., 2009), 15 MAbs,
and 15 MAbs reacted exclusively with the DENV-1 NS1, DENV-2 NS1,Table 1
Characteristics of representative MAbs against the NS1 protein from each DENV serotype.
Origin of
MAbs
Clones Isotypes ELISA results from recombinant NS1 Western b
NS1
DENV-1 DENV-2 DENV-3 DENV-4 DENV-1
DENV-1 5A48A3 IgG1 + − − − +
DENV-1 5A65A2 IgG1 + − − − +
DENV-1 5B29A1 IgG1 + − − − +
DENV-1 5B71A8 IgG1 + − − − +
DENV-1 5C29A3 IgG1 + − − − +
DENV-1 5E68A17 IgG1 + − − − +
DENV-1 5D25A2 IgG1 + − − − +
DENV-1 5A30A3 IgG2a + − − − +
DENV-1 5A70A5 IgG2a + − − − +
DENV-1 5A75A9 IgG2a + − − − +
DENV-1 5A78A3 IgG2a + − − − +
DENV-1 7F9A26 IgG1 + + + + +
DENV-1 7F2A2 IgG2b + + + + +
DENV-1 7A7A2 IgG1 + + + + +
DENV-2 3D5A1 IgG1 + + + + +
DENV-1 6E10A2 IgG2a + + + + +
DENV-2 5A11A5 IgG1 + + + + +
DENV-2 5A27A3 IgG1 + + + + +
DENV-2 4C69A19 IgG1 + + + + +
DENV-3 6D43A59 IgG1 + + + + +
DENV-3 6A17A1 IgG1 + + + + +
DENV-3 6D29A6 IgG1 + + + + +
DENV-2 5A7A5 IgG1 + + + + +
DENV-3 6D33A2 IgG1 + + + + +
DENV-1 8E6A2 IgG2b + + + + +
DENV-1 5C25A1A4 IgG2a + + + + +
DENV-1 5F78A6 IgG1 + + + + +
DENV-1 5C70A8 IgG2a + + + + +
DENV-1 5F60A5 IgG1 + + + + +
DENV-1 7H9A10 IgG1 + + + + +
DENV-2 5C22A5 IgG2b + + + + +
DENV-4 2C20A11 IgG1 − − − + −
DENV-4 1F8A9 IgG2a + + + + +
DENV-4 1F34A4 IgG2b + + + + +
DENV-4 1D30A4 IgG1 + + + + +
DENV-4 1E5A2 IgG1 + + + + +
DENV-4 1A19A3 IgG1 + + + + +
DENV-4 1E8A9 IgG1 + + + + +
DENV-1 7E9A2 IgG2a + + + + +
DENV-4 7E1A4 IgG1 + + + + +
DENV-2 1F2A27 IgG1 + + + + +
DENV-2 1F75A4 IgG1 + + + + +
DENV-2 1D36A3 IgG1 + + + + +DENV-3 NS1, and DENV-4 NS1 proteins, respectively, in ELISA plus
Western blotting or IFA assays. The remaining 74 MAbs showed
various patterns of cross-reactivity with the four DENV serotypes. The
characteristics of representative MAbs are summarized in Table 1 and
Fig. 1.
Identiﬁcation of serotype- and group-speciﬁc B-cell epitopes on NS1
protein using MAbs
A total of 149 MAbs described above were tested for binding to a
set of overlapping 15-residue synthetic peptides that spanned the
entire amino acid sequence of NS1 from DENV-1 by ELISA (Table 2).
The data for MAbs speciﬁcally reactive with the overlapping peptides
are summarized in Table 1. As expected, all of the serotype-speciﬁc
MAbs to each virus serotype reacted exclusively with NS1 from the
corresponding serotypes; for example, MAbs speciﬁc for DENV-2,
DENV-3, or DENV-4 failed to react with any of the synthetic peptides
derived from DENV-1 NS1. Among the 25 DENV-1 serotype-speciﬁc
MAbs, six MAbs (5A48A3, 5A65A2, 5B29A1, 5B71A8, 5C29A3, and
5E68A17) showed a strong reaction with peptide 1 (residues 1–15);
one MAb (5D25A2) reacted speciﬁcally with peptide 8 (residues 71–
85); four MAbs (5A30A3, 5A70A5, 5A75A9, and 5A78A3) reactedlot results from recombinant IFA results from cells infected by: Binding
Peptide
DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4
− − − + − − − 1
− − − + − − − 1
− − − + − − − 1
− − − + − − − 1
− − − + − − − 1
− − − + − − − 1
− − − + − − − 8
− − − + − − − 35
− − − + − − − 35
− − − + − − − 35
− − − − − − − 35
+ + + + + + + 3
+ + + + + + + 3
+ + + + + + + 3
+ + + + + + + 3
+ + + + + + + 12
+ + + + + + + 12
+ + + + + + + 12
+ + + + + + + 12
+ + + + + + + 12
+ + + + + + + 12
+ + + + + − + 12
+ + + + + + + 12
+ + + + + + + 12
+ + + + + − + 20
+ + + + + + + 20
+ + + + − + − 20
+ + + + + + + 20
+ + + + + + + 20
+ + + + + + + 20
+ + + + + + + 20
− + + + − + + 20
+ + + + + + + 20
+ + + + + + + 20
+ + + + + + + 20
+ + + + + + + 20
+ + + + − − + 20
+ + + + − + + 20
+ + + + − − − 27
+ + + + + + + 27
+ + + + + + + 30
+ + + + + + + 30
+ + + + + + + 30
Fig. 1. Characteristics of the serotype speciﬁcity and cross-reactivity of MAbs against the NS1 protein by IFA andWestern blot. (A) IFA analysis of representative MAbs against DENV
NS1. C6/36 cell infected with four serotypes of DENV. The cells were incubated with MAb against DENV NS1, followed by incubation with FITC-conjugated goat anti-mouse IgG. The
green colour represents the positive signal of the MAb reactivity. a: The representative serotype-speciﬁc DENV-1 NS1 MAb 5A48A3; b: The representative group-speciﬁc DENV NS1
MAb 1F75A4. Original magniﬁcations 200×. (B) Western blot analysis of representative MAbs against DENV NS1. The 6xHis-tagged recombinant NS1 protein from each DENV
serotype were separated on the sodium dodecyl sulfate–10% polyacrylamide gel and transferred onto a nitrocellulose membrane. The membranes were reacted with MAbs against
DENV NS1 and control anti-HisMAb, respectively. a: The representative serotype-speciﬁc DENV-1 NS1MAb 5A48A3; b: The representative group-speciﬁc DENVNS1MAb 1F75A4; c:
Control anti-His MAb. Lanes 1: Puriﬁed DENV-1 NS1; Lanes 2: Puriﬁed DENV-2 NS1; Lanes 3: Puriﬁed DENV-3 NS1; Lanes 4: Puriﬁed DENV-4 NS1.
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(1F31A5, 1C2A25, and 7E5A11) displayed weaker binding to peptide
12 (residues 111–125; mean OD450 0.427; data not shown). The
results of DENV-1 serotype-speciﬁc MAbs speciﬁcally reactive with
the overlapping peptides are summarized in Fig. 2. The speciﬁcTable 2
Sequences of the overlapping 15-mer synthetic peptides derived from DENV-1 NS1 (Hawa
Peptide no. Amino acid sequence
1 1DSGCVINWKGRELKC15
2 11RELKCGSGIFVTNEV25
3 21VTNEVHTWTEQYKFQ35
4 31QYKFQADSPKRLSAA45
5 41RLSAAIGKAWEEGVC55
6 51EEGVCGIRSATRLEN65
7 61TRLENIMWKQISNEL75
8 71ISNELNHILLENDMK85
9 81ENDMKFTVVVGDVSG95
10 91GDVSGILTQGRKMIG105
11 101RKMIGPQPMEHKYSW115
12 111HKYSWKSWGKAKIIG125
13 121AKIIGADVQNTTFII135
14 131TTFIIDGPNTPECPD145
15 141PECPDDQRAWNIWEV155
16 151NIWEVEDYGFGIFTT165
17 161GIFTTNIWLKLRDSY175
18 171LRDSYTQVCDPRLMS185reactivity of peptides with MAbs was further conformed by
competitive inhibition experiments (Supplemental data). The MAbs,
which reactivity with peptide 1 (residues 1–15) and peptide 12
(residues 111–125), respectively, binding to solid phase DENV-1 NS1
protein were efﬁciently inhibited (N75% inhibition) by theii strain, GenBank X69395).
Peptide no. Amino acid sequence
19 181PRLMSAAIKDSKAVH195
20 191SKAVHADMGYWIESE205
21 201WIESEKNETWKLARA215
22 211KLARASFIEVKTCVW225
23 221KTCVWPKSHTLWSNG235
24 231LWSNGVLESEMIIPK245
25 241MIIPKIYGGPISQHN255
26 251ISQHNYRPGYSTQTA265
27 261STQTAGPWHLGKLEL275
28 271GKLELDFDLCEGTTV285
29 281EGTTVVVDEHCGNRG295
30 291CGNRGPSLRTTTVTG305
31 301TTVTGKIIHEWCCRS315
32 311WCCRSCTLPPLRFKG325
33 321LRFKGEDGCWYGMEI335
34 331YGMEIRPVKDKEENL345
35 338VKDKEENLVKSLVSA352
Fig. 2. Three serotype-speciﬁc epitopes of DENV-1 mapped using serotype-speciﬁc MAbs. (A) ELISA reactivity of serotype-speciﬁc MAbs and mouse sera with peptides derived from
the NS1 protein. Each bar indicates antibody reactivity as determined by the mean absorbance. (B) Sequence alignment of the indicated NS1 amino acid residues corresponding to
serotype-speciﬁc epitopes among representative strains of ﬂavivirus isolates.
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peptide 8 and 35, respectively, binding to solid phase DENV-1 NS1
protein were partially inhibited (32–73% inhibition) by the
corresponding soluble peptides, but the binding of MAbs were
completely inhibited (61–91% inhibition) when increasing soluble
peptides at a concentrations of 100 μg/mL. The remaining 11 MAbs,
three MAbs also showed weaker reaction with a numbers of the other
peptides (data not shown), but the binding of MAbs to DENV-1 NS1
protein was not inhibited (b25% inhibition) by the corresponding
soluble peptide even increasing concentrations of soluble peptides,
which were probably due to nonspeciﬁc reactions. Another 8 MAbs,
which did not react with DENV-1 NS1 onWestern blots, failed to bind
any of the overlapping peptides, suggesting that these MAbs were
directed against conformational or discontinuous epitopes. We
compared NS1 sequences in different members of the ﬂavivirus
family by aligning NS1 residues 1–15, 71–85, 111–125, and 338–352
from DENV-1, -2, -3, -4, WNV, YFV, and JEV. Alignment revealed that
the amino acid sequences of peptide 1 (residues 1–15), peptide
8 (residues 71–125), and peptide 35 (residues 338–352) were
completely conserved among DENV-1 serotypes, but different
among the ﬂaviviruses, suggesting that three regions of NS1, i.e.
peptide 1 (residues 1–15), peptide 8 (residues 71–125), and peptide
35 (residues 338–352), were DENV-1 serotype speciﬁc epitopes.
Further studies were carried out to characterize the cross-
reactivity of 74 MAbs to the synthetic NS1 peptides; these MAbs
had shown different cross-reactivity patterns to four DENV serotypes.
As shown in Table 1, a set of 4 MAbs (three MAbs derived from DENV-1 immunized mice and one MAb derived from DENV-2 immunized
mice) reacted speciﬁcally with peptide 3 (residues 21–35); 9 MAbs
(one MAb derived from DENV-1 immunized mice, four MAbs derived
from DENV-2 immunized mice, and four MAbs derived from DENV-3
immunized mice) reacted speciﬁcally with peptide 12 (residues 111–
125); 14 MAbs (six MAbs derived from DENV-1 immunized mice, one
MAb derived from DENV-2 immunized mice, and seven MAbs derived
from DENV-4 immunized mice) reacted speciﬁcally with peptide 20
(residues 191–205); 2 MAbs (one MAb derived from DENV-1
immunized mice and one MAb derived from DENV-4 immunized
mice) reacted speciﬁcally with peptide 27 (residues 261–275); and 3
MAbs derived fromDENV-2 immunizedmice reacted speciﬁcally with
peptide 30 (residues 291–305). The results of cross-reactive MAbs
speciﬁcally reactive with the overlapping peptides are summarized in
Fig. 3. The speciﬁc reactivity of peptides with MAbs was further
conformed by competitive inhibition experiments (Supplemental
data). The binding of MAbs to solid phase DENV-1 NS1 protein was
efﬁciently inhibited (N75% inhibition) by the corresponding soluble
peptide. The remaining 42 MAbs, some showed weaker reaction with
a numbers of the other peptides (data not shown) but the binding of
MAbs to solid phase DENV-1 NS1 protein was not inhibited (b25%
inhibition) by the corresponding soluble peptide, which were
probably due to nonspeciﬁc reactions; some did not react with any
of the peptides, which were probably directed against conformational
or discontinuous epitopes or that the epitopes they bound to on NS1
did not exist. NS1 sequences from different members of the ﬂavivirus
family were compared by aligning NS1 residues 21–35, 111–125,
Fig. 3. Five group-speciﬁc epitopes of DENV mapped using cross-reactive MAbs. (A) ELISA reactivity of cross-reactive MAbs and mouse sera with peptides derived from the NS1
protein. Each bar indicates antibody reactivity as determined by the mean absorbance. (B) Sequence alignment of the indicated NS1 amino acid residues corresponding to group-
speciﬁc epitopes among representative strains of ﬂavivirus isolates.
294 Y. Chen et al. / Virology 398 (2010) 290–298191–205, 261–275, and 291–305 from DENV-1, -2, -3, -4, WNV, YFV,
and JEV. This comparison revealed that the amino acid sequences in
these regions were conserved among the four DENV serotypes, but
different among the other ﬂaviviruses (WNV, YFV, and JEV),suggesting that ﬁve regions of NS1, i.e. peptide 3 (residues 21–35),
peptide 12 (residues 111–125), peptide 20 (residues 191–205),
peptide 27 (residues 261–275), and peptide 30 (residues 291–305),
were group-speciﬁc epitopes.
Fig. 4. Immunodominant epitopemapping of NS1 protein usingmouse antisera. Reactivity of mouse antiserawith synthesized overlapping peptides spanning the entire sequences of the
NS1 protein derived from DNEV-1 was determined as described in Materials and methods. The y-axis shows the mean reactivity (absorbance/cutoff) of sera from immunizedmice with
synthetic peptides plus standard error bars. The data represent the average of two independent experiments. The signiﬁcance of the differences in ELISA reactivity of peptides with sera
fromeachDENV immunizedmicewas analyzed using the SPSS statistical package, version 13.0, for one-wayANOVA analysis, (⁎): The reactivity of sera fromDENV-1NS1 immunizedmice
with peptide 1 was signiﬁcantly higher than the reactivity of sera from mice immunized with the other three DENV serotypes (Pb0.05). ( ): The reactivity of sera from DENV-1 NS1
immunizedmicewith peptide 3was similar to that of sera fromDENV-2NS1 immunizedmice signiﬁcantly higher than that of sera fromDENV-3 and DENV-4 immunizedmice (Pb0.05).
(#): The reactivity of sera frommice immunizedwithDENV-1, -2, -3, or -4NS1with peptides 8, 12, 20, 27, and 35was not signiﬁcantly different (PN0.05), and the reactivity of peptides 12,
20, and 27with highmean of absorbance/cut off value ratio between the four DENV immunizedmice sera. (§): The reactivity of sera fromDENV-3 NS1immunizedmice with peptide 30
was signiﬁcantly higher than the reactivity of sera from DENV-1 NS1 immunized mice but was similar to that of sera from DENV-2 and DENV-4 NS1 immunized mice (Pb0.05).
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epitopes on NS1 using mouse antisera
Antisera from 27 mice, each injected with one of the four DENV
serotypes (9 mice with DENV-1 NS1, 4 mice with DENV-2 NS1, 4 mice
with DENV-3 NS1, and 10 mice with DENV-4 NS1), were analyzed for
binding to a set of overlapping synthetic peptides. The results of
binding to the immunodominant serotype- and group-speciﬁc
epitopes are summarized in Fig. 4. Peptide 1 (residues 1–15) showed
high immunoreactivity, i.e. a high mean absorbance/cut-off ratio,
with sera from DENV-1 NS1-immunized mice. This suggests that the
region of NS1 comprising residues 1–15 is a serotype-speciﬁc
immunodominant epitope. Peptide 3 (residues 21–35) reacted with
sera from DENV-1- and DENV-2-immunized mice; the high mean
absorbance/cut-off ratio was different from that of sera from DENV-3-
and DENV-4-immunizedmice, suggesting that this region is a DENV-1
and DENV-2 serotype-speciﬁc immunodominant epitope. Peptides 12
(residues 111–125), 20 (residues 191–205), and 27 (residues 261–
275) had high cross-immunoreactivity with sera from mice immu-
nized with each of the four DENV serotypes. This suggests that the
three regions are group-speciﬁc immunodominant epitopes among
the four DENV serotypes. Taken together, these data suggest that the
most immunoreactive epitopes on the NS1 protein involve amino acid
residues 1–15, 21–35, 111–125, 191–205, and 261–275.
Identiﬁcation of conserved serotype- and group-speciﬁc B-cell epitopes
on NS1 by sequence alignment
There are 675 DENV-1, 622 DENV-2, 396 DENV-3, and 64 DENV-4
isolate sequences available in theNCBI Entrez protein database (http://Table 3
Sequence alignment of the deﬁned group-speciﬁc epitopes corresponding to NS1 amino ac
Peptide no. Common sequence on
NS1 in the four dengue
serotype isolates
Conserved virus strai
DENV-1
3 25VHTWTEQYKFQ35 671/675 (99.4)
12 112KYSWKS/TWGKAK123b 641/675 (95)
20 193AVHADMGYWIES204 674/675 (99.9)
27 266GPWHLGKLE274 674/675 (99.9)
30 294RGPSLRTTT302 672/675 (99.6)
a The DENV sequence used in this alignment were obtained from the NCBI Entrez protei
b There is a single amino acid substitution (117S→T) in the DENV-2, -3, and -4 isolates.www.ncbi.nlm.nih.gov/protein/) that can be used for sequence
alignment analysis. Alignment of the serotype-speciﬁc epitopes (resi-
dues1–15, 71–85, and338–352)ofNS1 fromDENV-1 isolates revealed a
high degree of conservation of 100% homology for the 3 epitopes in 668,
633, and 532 of the 675 DENV1 isolates, respectively, with amino acid
identity ranging from 78.8–99%. Alignment of group-speciﬁc epitopes
(residues 21–35, 111–125, 191–205, 261–275, and 291–305) on NS1
from DENV-1, -2, -3, and -4 isolates revealed that the amino acid
sequences 25VHTWTEQYKFQ35, 112 KYSWKSWGKAK123, 193AVHADM-
GYWIES
204
, 266GPWHLGKLE274, and 294RGPSLRTTT302 were similar
among the serotypes (Table 3), indicated that these regions of NS1 are
highly conserved among the four DENV serotypes.
Discussion
DENV NS1 effectively induces speciﬁc B- and T-cell responses to
elicit protection against virus infection (Falconar et al., 1994; Green
et al., 1997; Mathew et al., 1998). The identiﬁcation of epitopes on
NS1 is important for designing subunit vaccines and for developing
serological tests that can differentiate infections caused by the four
DENV serotypes. B-cell epitopes are more commonly characterized
based on their amino acid sequences than are T-cell epitopes (Carter
and Loomis-Price, 2004). In this study, we producedMAbs and sera by
immunizing mice with the NS1 protein from each DENV serotype.
These MAbs and sera were used for detailed characterization of the
immunodominant serotype- and group-speciﬁc B-cell epitopes onNS1
based on their binding to synthetic peptides from the NS1 sequence of
the DENV-1 serotype.
Using a panel of well-characterized DENV-1 serotype-speciﬁc
MAbs, we identiﬁed three novel serotype-speciﬁc B-cell epitopes,id residues in the four DENV serotype isolates.a
ns/all virus isolates (% identity)
DENV-2 DENV-3 DENV-4
616/622 (99.0) 391/396 (98.7) 59/64 (92.2)
578/622 (92.9) 381/396 (96.2) 63/64 (98.4)
610/622 (98.1) 393/396 (99.2) 63/64 (98.4)
605/622 (97.3) 392/396 (99) 64/64 (100)
622/622 (100) 388/396 (98) 64/64 (100)
n database (http://www.ncbi.nlm.nih.gov/protein/).
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Alignment of amino acid sequences from a number of DENV-1 isolates
indicated that the three serotype-speciﬁc B-cell epitopes are highly
conserved among DENV-1 strains. In addition, we identiﬁed ﬁve
group-speciﬁc B-cell epitopes that were associated with NS1 amino
acid residues 21–35, 111–125, 191–205, 261–275, and 291–305 based
on their reactivity with four DENV serotype cross-reactive MAbs.
Sequence alignment of the region encompassing the ﬁve group-
speciﬁc B-cell epitopes showed that the predominant residues
25VHTWTEQYKFQ35, 112KYSWKSWGKAK123, 193AVHADMGYWIES204,
266GPWHLGKLE274, and 294RGPSLRTTT302 are highly conserved among
isolates from the four DENV serotypes.
Furthermore, using a combination of speciﬁc MAbs and sera from
immunizing mice with each DENV serotype, we showed that several
B-cell epitopes on the NS1 protein identiﬁed in this study demon-
strated that there are at least ﬁve immunodominant epitopes on NS1
(residues 1–15, 21–35, 111–125, 191–205, and 261–275). Our results
indicated that the NS1 protein contains multiple immunodominant B-
cell epitopes that are capable of eliciting strong antibody responses.
By studying the ﬁve immunodominant epitopes, we found that
peptide 1, corresponding to NS1 amino acid residues 1–15, showed
signiﬁcantly higher reactivity with sera from DENV-1-immunized
mice sera and with six of 25 serotype-speciﬁc MAbs (24%; Figs. 2 and
4). This suggests that this region is an immunodominant serotype-
speciﬁc epitope on DENV-1 NS1. This immunodominant epitope is
consistent with reports by Huang (Huang et al., 1999), who identiﬁed
a peptide, residues 1–15 derived from DENV-2 NS1, as an immuno-
dominant epitope that reacted with most sera from four DENV
infection patients. Our independent identiﬁcation of residues 1–15
from DENV-1 NS1 as the exclusive epitope responsible for the
reactivity of serotype-speciﬁc MAbs and antisera from DENV-1
immunized mice is strong evidence that this is a serotype-speciﬁc
epitope. However, further study is needed to determine the speciﬁc
binding activity of this region using sera from dengue patients. In
addition, an immunodominant epitope that mapped to residues 111–
125 in the present study appeared to deﬁne a group-speciﬁc B-cell
epitope similar to that identiﬁed by Falconar (Falconar et al. 1994).
We subsequently determined that this region, comprising the amino
acid sequence 112KYSWKSWGKAK123, is highly conserved among the
four DENV isolates (Table 3); there is a substitution of residues117 S
by T in DENV-2, -3, -4 isolates, but this amino acid substitution is
antigenically silent, as demonstrated by Falconar (Falconar et al.,
1994). Other study reported that the NS1 amino acid residues
111HKYSWK116 from DENV-1 was deﬁned as a DENV-1 serotype-
speciﬁc B-cell epitope on NS1 by a DENV-1 serotype speciﬁcMAb (Wu
et al., 2001). They suggested that His111 was the most important
amino acid residue for antibody binding speciﬁcity, since a substitu-
tion of residues111 H by L in DENV-2, -3, and -4 isolates, markedly
decreased the speciﬁcity of MAb reactivity. Interestingly, in this study
we found that residues 111HKYSWKSWGKAKIIG125 of NS1 reacted
more strongly with cross-reactive MAbs than with serotype-speciﬁc
MAbs (3 DENV-1 serotype-speciﬁc MAbs reacted weakly). Consider-
ing both data from previous reports and our own ﬁndings, we suggest
that the NS1 epitope residues 111–125 is most likely an immunodo-
minant group-speciﬁc epitope. The other group-speciﬁc epitopes
described here, comprising amino acid residues 21–35 on NS1, is
distinct from the epitope reported by Falconar (Falconar et al., 1994).
In their report, the 25VHTWTEQYK33 region only reacted with DENV-2
serotype-speciﬁc MAbs; when this region had additional ﬂanking
residues on the N or C-terminus, the serotype-speciﬁc MAbs showed
weaker binding activity, suggesting that additional ﬂanking residues
on 25VHTWTEQYKFQ35 on the N or C-terminus is probably for cross-
reactive MAb binding. Further investigation will determine whether
amino acid substitution in peptide 3 (residues 21–35) affects antibody
binding and which amino acid(s) on the peptide are crucial for
antibody binding.Understanding the MAb-speciﬁc epitope-binding sites on DENV NS1
and characterizing its immunodominant sites may provide valuable
information for thedevelopment of denguediagnostic tests andvaccines.
Since amino acid sequences for the four DENV serotypes showhomology
ranges from 63.2% to 78.7% (Westaway and Blok, 1997), share antigenic
epitopes inducing cross-reactive antibodies among ﬂaviviruses has been
a diagnostic challenge. Currently, serological assays cannot distinguish
the four DENV serotypes and other ﬂaviviruses. The MAb-speciﬁc
epitopes reported here might aid development of diagnostic tests that
can discriminate between different DENV serotypes. In a previous study,
we successfully developed two serotype-speciﬁc NS1 antigen assays
using serotype-speciﬁc MAbs to distinguish the DENV serotypes (Qiu et
al., 2009; Xu et al., 2006). Thus, the unique serotype-speciﬁc B-cell
epitopes located on NS1 that are reported in the present study may be
useful for accurate serodiagnosis of DENV infection.
Identiﬁcation of novel antigenic cross-reactive epitopes for the four
DENV serotypes should provided insights into the humoral immunity
of dengue disease. The pathogenesis of DHF or DSS is not well
understood. Several studies have reported that antibody responses to
NS1play a role in the development of DHF orDSS (Chen et al., 2009; Lin
et al., 2005; Sun et al., 2007). Determination of the epitopes onNS1 that
are responsible for the harmful vs. beneﬁcial effects of this protein
might provide greater understanding of the pathogenesis of dengue
disease and speed NS1-based vaccine development. Further studies
are needed to determine the epitope proﬁles in clinical serum samples
and to analyze the functional roles of epitope-speciﬁc MAbs in dengue
pathogenesis and immunoprotection.
Materials and methods
Viruses
The four DENV serotype strains (DENV-1, Hawaii; DENV-2, New
Guinea-C; DENV-3, Guanxi-80-2; and DENV-4, H241) used in this
study were obtained from the Center for Disease Control and
Prevention in Guangzhou, P. R. China. The viruses were propagated
in C6/36 cells in Eagle's minimal essential medium at 33 °C for 3 to
5 days. After cytopathic effects were observed, the viral culture
supernatants and infected cell lysates were collected and kept frozen
at −80 °C until use.
Recombinant NS1 protein
Recombinant NS1 proteins from the four DENV serotypes were
prepared as described previously (Qiu et al., 2009; Xu et al., 2006).
Brieﬂy, the gene encoding the NS1 protein from each DENV serotype
was cloned into pQE30 (Qiagen, Hilden, Germany) in-frame and
downstream of the 6xHis tag coding sequence. The 6xHis-tagged
recombinantNS1protein fromeachDENV serotypewas expressed in an
Escherichia coli host strain (M15) and puriﬁed by Ni-nitrilotriacetic acid
afﬁnity chromatography (Qiagen) according to the manufacturer's
instructions.
Peptide synthesis
A set of 35 overlapping, biotinylated 15-mer peptides that
encompassed the entire NS1 protein amino acid sequence from the
DENV-1 serotype (Hawaii strain X69395.1) were synthesized commer-
cially by Huachen Biological Technology Co. Ltd (Xi'an, P. R. China).
Peptides were 15 amino acid residues in length, with adjacent peptides
overlapping by ﬁve residues (Table 2). Synthesized peptides were
puriﬁed (ﬁnal purityN90% as determined by high-performance liquid
chromatography. The purity of each peptide was conﬁrmed by laser
desorptionmass spectrometry. Freeze-dried peptides were dissolved in
100% dimethyl sulfoxide to an approximate concentration of 1 mg/mL
and stored at−80 °C until use.
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BALB/cmalemice (4–6weeks old)were immunized intradermally
with a combination of puriﬁed recombinant NS1 protein derived from
each DENV serotype and with the corresponding DENV-infected cell
culture supernatant (inactive) as an immunogen mixed with Freund's
complete adjuvant (Sigma-Aldrich). The immunogen was boosted
with Freund's incomplete adjuvant at 10-day intervals. Mouse
antisera were collected after ﬁve immunizations.
Production and characterization of MAbs
The production and identiﬁcation of MAbs against the NS1 protein
from the four DENV serotypes was performed as described previously
(Qiu et al., 2009; Xu et al., 2006). Brieﬂy, BALB/c mice were immunized
as described above. The spleenocytes from the immunized mice were
harvested and fused with NS-1 myeloma cells. The hybridoma cell lines
were screened by indirect ELISA using recombinant NS1 protein and
DENV-infected cell lysate as coating antigens respectively. The screening
was conﬁrmed by an IFA that detected MAb binding on C6/36 cells
infected with each DENV serotype, as described previously (Che et al.,
2005; Qiu et al., 2009; Xu et al., 2006). Positive hybridoma cells were
cloned by limiting dilution. The serotype speciﬁcity and cross-reactivity
of the MAbs were evaluated by ELISA and Western blot analysis using
recombinant NS1 proteins from the four DENV serotypes as well as by
using cell lysates from cells infected with each DENV serotype. The
isotypes of the MAbs were determined using a commercially available
mouseMAb isotyping kit (Zymed Laboratories, Carlsbad, CA). TheMAbs
were puriﬁed by using protein G column chromatography (Amersham-
Pharmacia) according to the manufacturer's instructions.
Epitope mapping using ELISA
The reactivity of mouse antisera and MAbs with the overlapping,
biotinylated peptides were determined by ELISA. Brieﬂy, 96-well
microplates (Costar Corning Inc., Corning, NY) were coated with
100 μL/well streptavidin (5 μg/mL; Sigma-Aldrich) in 0.1M carbonate
buffer (pH 9.6) at 4 °C overnight. Wells were blocked overnight at 4 °C
using a blocking reagent. After removing the blocking solution, a series
of biotinylated peptides at concentration of 5 μg/mL were added and
incubated for 2 h at room temperature. After the plates were washed,
mouse antisera at a dilution of 1:1000 or MAb at a concentration of
5 μg/mL was added and incubated for 30 min at room temperature.
After the plates were washed, 1:1,000 dilution HRP-conjugated goat-
antimouse IgG (Zymed Laboratories, was added and incubated for
30 min at room temperature. After washing, tetramethylbenzidine
(KPL, Gaithersburg, MD) solution was added; after incubation for
10 min, and the reaction was stopped with 0.3 M sulfuric acid. The
absorbance was measured at 450 nm in a microplate autoreader (Bio-
Tek Instruments, USA). Each sample was tested in duplicate wells. An
irrelevant MAb and normal mouse serum were used as controls. The
reactivity of the MAb with the synthesized peptides was considered
positive when the mean absorbance value was ten-fold greater than
themean absorbance value of theMAb control. The reactivity ofmouse
antiserum with the synthesized peptides was calculated using the
ratio of the mean absorbance/cut-off value. The cut-off value was
determined for each peptide by incubation with sera from ﬁve normal
mice. The mean absorbance using the ﬁve normal mice sera was
considered the cutoff value for a peptide.
Competitive ELISA
Microplates (Costar Corning Inc) were coated with 100 μL/well of
DENV-1 NS1 protein at concentration of 1 μg/mL in coating buffer. The
dilutions of MAbs giving an optical density of approximately 2.0 were
selected for subsequent competitive experiments. The MAb atselected dilutions in 60 μL of PBS containing 0.1% of BSA was mixed
with the 60 μL of PBS containing 0.1% of BSA containing increasing
concentrations of soluble synthetic peptides (ranging between 1.56–
100 μg/mL). After 1 h of incubation at 37 °C, 100 μL of mixtures were
transferred into the microplates precoated DENV-1 NS1 protein and
the plates incubated for 1 h at 37 °C. After the plates were washed,
100 μL/well of a 1:1000 dilution HRP-conjugated goat antimouse IgG
(Zymed Laboratories) was added and incubated for 30 min at 37 °C.
After further washing, 100 μL/well of tetramethylbenzidine (KPL)
solution was added, and the reaction was stopped after incubation for
10 min with 0.3 M sulfuric acid. The absorbance was measured at
450 nm in a microplate autoreader (Bio-Tek Instruments, USA). The
mixture of sameMAb and PBS without synthetic peptides was used as
a control. The percentage of inhibitionwas calculated by the following
formula: [1− (OD450 of the test well/OD450 of the control
well)]×100% (where OD450 is the optical density at 450 nm). The
results were described as follows: inhibition of N75% represented
competitive binding, inhibition from 25% to 75% represented
relatively competitive binding, and inhibition of b25% represented
noncompetitive binding.
Statistical analysis
The SPSS statistical package, version 13.0, was used to perform
one-way ANOVA analysis to compare the reactivity of the synthetic
peptides with sera from mice immunized with the four DENV
serotypes in the ELISA i.e. to determine whether reactivity was
signiﬁcantly different. P values b0.05 were considered statistically
signiﬁcant.
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